Englerin derivatives for treatment of cancer

US11098054B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Sciences · US
• FUNDACIÓ INSTITUT CAT ALÁ DINVESTIGACIÓ QUÍMICA (ICIQ) · ES
• University Of Delaware · US
• University of Leeds · GB
• Universitat Rovira I Virgili (URV) · ES

Inventors

• John A. Beutler · Braddock, US
• Antonio M. Echavarren · Tarragona, ES
• William Chain · Newark, US
• David John BEECH · Leeds, GB
• Zhenhua Wu · Huzhou City, CN
• Jean-Simon Suppo · Tarragona, ES
• Fernando Bravo · Valls, ES
• Hussein Rubaiy · Leeds, GB

Key dates

• Filing date: Jul 5, 2018
• Grant date: Aug 24, 2021
• Expiry date: Jul 5, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed is a compound of formula (I) in which a, R1-R5 and X1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.